Mostrar el registro sencillo del ítem
dc.contributor.author | Perez-Gomez, Beatriz | |
dc.contributor.author | Pastor-Barriuso, Roberto | |
dc.contributor.author | Perez-Olmeda, Mayte | |
dc.contributor.author | Hernán, Miguel A | |
dc.contributor.author | Oteo-Iglesias, Jesus | |
dc.contributor.author | Fernandez de Larrea-Baz, Nerea | |
dc.contributor.author | Fernandez-Garcia, Aurora | |
dc.contributor.author | Martín, Mariano | |
dc.contributor.author | Fernandez-Navarro, Pablo L | |
dc.contributor.author | Cruz, Israel | |
dc.contributor.author | Sanmartín, Jose L | |
dc.contributor.author | Paniagua-Caparros, Jose Leon | |
dc.contributor.author | Muñoz-Montalvo, Juan F | |
dc.contributor.author | Blanco, Faustino | |
dc.contributor.author | Yotti-Alvarez, Raquel | |
dc.contributor.author | Pollan-Santamaria, Marina | |
dc.contributor.author | ENE-COVID Study Group | |
dc.date.accessioned | 2022-05-09T09:07:31Z | |
dc.date.available | 2022-05-09T09:07:31Z | |
dc.date.issued | 2021-11 | |
dc.identifier.citation | J Clin Epidemiol. 2021 Nov;139:240-254. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14323 | |
dc.description.abstract | Objectives: To characterize asymptomatic SARS-CoV-2 infections and develop a symptom-based risk score useful in primary healthcare. Study design and setting: Sixty-one thousand ninty-two community-dwelling participants in a nationwide population-based serosurvey completed a questionnaire on COVID-19 symptoms and received an immunoassay for SARS-CoV-2 IgG antibodies between April 27 and June 22, 2020. Standardized prevalence ratios for asymptomatic infection were estimated across participant characteristics. We constructed a symptom-based risk score and evaluated its ability to predict SARS-CoV-2 infection. Results: Of all, 28.7% of infections were asymptomatic (95% CI 26.1-31.4%). Standardized asymptomatic prevalence ratios were 1.19 (1.02-1.40) for men vs. women, 1.82 (1.33-2.50) and 1.45 (0.96-2.18) for individuals <20 and ≥80 years vs. those aged 40-59, 1.27 (1.03-1.55) for smokers vs. nonsmokers, and 1.91 (1.59-2.29) for individuals without vs. with case contact. In symptomatic population, a symptom-based score (weights: severe tiredness = 1; absence of sore throat = 1; fever = 2; anosmia/ageusia = 5) reached standardized seroprevalence ratio of 8.71 (7.37-10.3), discrimination index of 0.79 (0.77-0.81), and sensitivity and specificity of 71.4% (68.1-74.4%) and 74.2% (73.1-75.2%) for a score ≥3. Conclusion: The presence of anosmia/ageusia, fever with severe tiredness, or fever without sore throat should serve to suspect COVID-19 in areas with active viral circulation. The proportion of asymptomatics in children and adolescents challenges infection control. | es_ES |
dc.description.sponsorship | The ENE-COVID study was supported by the Spanish Ministry of Health, the Institute of Health Carlos III, and the Spanish National Health System. The funders were in- volved in the study logistics, but they had no role in study design or in the collection, analysis, interpretation of data, or the decision to submit the article for publication | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | COVID-19 | es_ES |
dc.subject | General population | es_ES |
dc.subject | Nationwide serosurvey | es_ES |
dc.subject | Prediction model | es_ES |
dc.subject | SARS-CoV-2 infection | es_ES |
dc.subject | Symptoms | es_ES |
dc.title | ENE-COVID nationwide serosurvey served to characterize asymptomatic infections and to develop a symptom-based risk score to predict COVID-19 | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 34126206 | es_ES |
dc.format.volume | 139 | es_ES |
dc.format.page | 240-254 | es_ES |
dc.identifier.doi | 10.1016/j.jclinepi.2021.06.005 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Ministerio de Sanidad (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1878-5921 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.jclinepi.2021.06.005 | es_ES |
dc.identifier.journal | Journal of Clinical Epidemiology | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.centro | ISCIII::Escuela Nacional de Sanidad | es_ES |
dc.repisalud.centro | ISCIII::Servicios Centrales | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |